Peptide research, regulation, discovery. Every story links to the peptide it’s about.
RSSIn 14,046 diverse US patients, tirzepatide took off about 13 percent of body weight in a year, semaglutide about 6, and the three older GLP-1 shots tied near 4. The trial ordering held, but tirzepatide's lead rests on just 386 people.
In a matched cohort of 1,798 carotid-stenting patients, those on a GLP-1 drug had fewer combined cardiovascular events over a year. The entire benefit was lower all-cause mortality. The heart attacks and strokes the composite is built on did not budge.
A meta-analysis of the few trials that actually weighed a test meal found GLP-1 drugs cut about 271 calories from a single sitting, with semaglutide and tirzepatide indistinguishable and real-world eating barely studied.
A meta-analysis of GLP-1 weight-loss trials found overall nonadherence was 37 percent lower than in control groups, but dropouts from side effects were 2.3 times as common, mostly gastrointestinal.
In eight pooled studies of heart-attack patients, adding a GLP-1 drug shrank the patch of dead heart muscle by about 10 points relative to the muscle at risk. The infarct result rests on just three small trials, and liraglutide carried most of the pump-function gain.
In veterans with diabetes and opioid use disorder, semaglutide and tirzepatide beat insulin and SGLT2 inhibitors on 12-month overdose risk but tied metformin, sulfonylureas, and DPP-4 drugs. The verdict flips with the comparator.
A Veterans Affairs cohort of 100,038 matched pairs found GLP-1 drugs tied to no more and no fewer lymphomas, leukemias, or myelomas than an older diabetes pill. Every confidence interval crossed the line of no difference.
In a 280-person Phase 2 trial, the oral GLP-1 drug HRS-7535 cut albuminuria 32 percent more than placebo in diabetic kidney disease, even though most patients were already on SGLT2 inhibitors and finerenone.
A data firm's analysis of nearly 30,000 adults 65 and older on tirzepatide found progressive muscle loss in 0.16 percent, with most frailty signals emerging only after six months.
A Cell Reports team acetylated the N-terminus of GLP-1 and semaglutide to build G protein-biased receptor agonists that recruit less beta-arrestin, and a 2.64 angstrom cryo-EM structure pins the bias to an outward swing of extracellular loop 3. Ac-semaglutide kept lowering glucose in obese mice three days after one dose.
A target trial emulation of 57,456 weight-management patients found semaglutide users had a 12 percent lower one-year risk of new diabetes than liraglutide users (HR 0.88). The gap was absent in the first six months (HR 0.99) and only emerged after (HR 0.80). With just 57 cardiovascular events, the study had no power to compare heart risk.
A quarter-million-patient database found GLP-1 drug users were no more likely, and often less likely, to have mouth problems. Reflux was the one exception worth watching.
In 235,200 matched adults, starting tirzepatide tracked with about three-quarters lower pulmonary embolism risk than lifestyle changes alone. The edge shrank to near even against semaglutide.
A US claims study emulating a randomized trial found that whichever flagship diabetes drug patients started on, adding the other modern class lowered heart events more than adding an older pill.
A drug-target Mendelian randomization study put major depression 18 percent lower and bipolar disorder 39 percent lower for genetically predicted GLP-1 receptor activation, cutting against two years of psychiatric-safety scares built on observational data.